US 11,744,947 B2
Glucose control system with control parameter modification
Edward R. Damiano, Acton, MA (US); and Firas H. El-Khatib, Allston, MA (US)
Assigned to BETA BIONICS, INC., Concord, MA (US)
Filed by BETA BIONICS, INC., Concord, MA (US)
Filed on Mar. 5, 2021, as Appl. No. 17/194,030.
Application 17/194,030 is a continuation of application No. 17/061,917, filed on Oct. 2, 2020, granted, now 10,940,267.
Application 17/061,917 is a continuation in part of application No. PCT/US2020/042269, filed on Jul. 16, 2020.
Application PCT/US2020/042269 is a continuation in part of application No. PCT/US2020/042195, filed on Jul. 15, 2020.
Application PCT/US2020/042195 is a continuation in part of application No. PCT/US2020/042198, filed on Jul. 15, 2020.
Claims priority of provisional application 63/037,472, filed on Jun. 10, 2020.
Claims priority of provisional application 62/987,842, filed on Mar. 10, 2020.
Claims priority of provisional application 62/910,970, filed on Oct. 4, 2019.
Claims priority of provisional application 62/911,017, filed on Oct. 4, 2019.
Claims priority of provisional application 62/911,143, filed on Oct. 4, 2019.
Claims priority of provisional application 62/874,975, filed on Jul. 16, 2019.
Claims priority of provisional application 62/874,964, filed on Jul. 16, 2019.
Claims priority of provisional application 62/874,977, filed on Jul. 16, 2019.
Claims priority of provisional application 62/874,959, filed on Jul. 16, 2019.
Claims priority of provisional application 62/874,950, filed on Jul. 16, 2019.
Claims priority of provisional application 62/874,972, filed on Jul. 16, 2019.
Claims priority of provisional application 62/874,968, filed on Jul. 16, 2019.
Claims priority of provisional application 62/874,934, filed on Jul. 16, 2019.
Claims priority of provisional application 62/874,928, filed on Jul. 16, 2019.
Claims priority of provisional application 62/874,954, filed on Jul. 16, 2019.
Prior Publication US 2021/0402090 A1, Dec. 30, 2021
Int. Cl. A61M 5/172 (2006.01); G16H 20/17 (2018.01); G16H 10/40 (2018.01); G16H 40/67 (2018.01); A61M 5/142 (2006.01); G16H 20/60 (2018.01)
CPC A61M 5/1723 (2013.01) [A61M 5/14244 (2013.01); G16H 10/40 (2018.01); G16H 20/17 (2018.01); G16H 20/60 (2018.01); G16H 40/67 (2018.01); A61M 2005/14208 (2013.01); A61M 2005/1726 (2013.01); A61M 2205/16 (2013.01); A61M 2205/3553 (2013.01); A61M 2205/3561 (2013.01); A61M 2205/3584 (2013.01); A61M 2205/3592 (2013.01); A61M 2205/50 (2013.01); A61M 2205/502 (2013.01); A61M 2205/505 (2013.01); A61M 2205/52 (2013.01); A61M 2230/201 (2013.01)] 29 Claims
OG exemplary drawing
 
1. A computer-implemented method of modifying therapy provided to a subject using a glucose control system, the method comprising:
by a hardware processor configured to generate a dose control signal for commanding administration of glucose control therapy in response to glucose level data received by the glucose control system,
causing first therapy to be delivered by the glucose control system to the subject during a first therapy period, wherein the first therapy is delivered based at least in part on a first value of a control parameter used by a control algorithm to generate the dose control signal;
obtaining a first therapy data comprising first glucose level data resulting from the delivery of the first therapy;
determining a first effect corresponding at least in part to the first therapy over a first time period, wherein the first effect is determined based at least in part on the first therapy data;
setting the control parameter to a second value that differs from the first value, wherein at least one of the first value or the second value is received via one or more of a plurality of control parameter value selection processes, wherein the plurality of control parameter value selection processes comprises:
receiving a value in response to a user interaction with a user interface;
receiving, via an electronic communications interface, a value specified by a system external to the glucose control system;
receiving a value corresponding to a prescription provided by a healthcare provider of the subject;
determining a value using physiological characteristics of the subject;
determining a value using demographic characteristics of the subject;
determining a value based on historical therapy data; and
determining a value based on a history of prior glucose control data;
causing second therapy to be delivered by the glucose control system to the subject during a second therapy period, wherein the second therapy is delivered based at least in part on the second value of the control parameter, and wherein setting the control parameter to the second value modifies the therapy provided to the subject;
obtaining a second therapy data comprising second glucose level data resulting from the delivery of the second therapy;
determining a second effect corresponding at least in part to the second therapy over a second time period, wherein the second effect is determined based at least in part on the second therapy data;
performing an analysis based at least in part on the first effect and the second effect to obtain a comparative assessment; and
determining, based at least in part on the comparative assessment, whether the second value for the control parameter results in an improvement in glucose control therapy for the subject.